TCGA-E9-A227-01A-11R-A157-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 32
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- ALLOGRAFT_REJECTION+0.350
- ANDROGEN_RESPONSE+0.320
- ADIPOGENESIS+0.310
- PEROXISOME+0.300
- BILE_ACID_METABOLISM+0.280
- COAGULATION+0.260
- KRAS_SIGNALING_UP+0.260
- PROTEIN_SECRETION+0.260
Top 10 suppressed
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V2-0.410
- MITOTIC_SPINDLE-0.380
- INTERFERON_ALPHA_RESPONSE-0.240
- APICAL_JUNCTION-0.140
- KRAS_SIGNALING_DN-0.140
- TGF_BETA_SIGNALING-0.130
- UV_RESPONSE_UP-0.120
- PANCREAS_BETA_CELLS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2EMW8ZG3 | low-grade glioma | — | 0.806 |
| 2 | SRR8518149 | — | F | 0.793 |
| 3 | 5c3c4b79-0682-4f19-96aa-071316a354d4 | — | — | 0.788 |
| 4 | SRR4195645 | — | — | 0.772 |
| 5 | SRR6013503 | — | cohortA1 | 0.770 |
| 6 | SRR11296843 | — | — | 0.763 |
| 7 | BS_66HQ3E4Z | pilocytic astrocytoma | — | 0.762 |
| 8 | 4bafe83e-072c-4042-bd3d-5f108391ed89 | — | — | 0.758 |
| 9 | SRR8518286 | — | F | 0.757 |
| 10 | SRR4195672 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |